Written question asked by Samantha Niblett (Labour) on Thursday, 16 April 2026, in the House of Commons. It was due for an answer on Wednesday, 22 April 2026 (named day). It was answered by Zubir Ahmed (Labour) on Wednesday, 22 April 2026 on behalf of the Department of Health and Social Care.

Urinary Tract Infections: Vaccination

Question: To ask the Secretary of State for Health and Social Care, what steps are required for vaccines for the prevention of recurrent urinary tract infections to obtain regulatory approval including an indicative timeline for licensing.

Answer: For any new medicine to be introduced to the United Kingdom market an application to the Medicines and Healthcare products Regulatory Agency (MHRA) is required. The MHRA is ready to support companies that are looking to introduce new medicines to the United Kingdom market, offering regulatory and scientific advice to help companies at any stage of the product development process. The MHRA has established procedures in place to review any applications we receive to evaluate the benefit risk of a product in relation to its quality, safety, and efficacy. The exact timeframe will depend on the type of submission the company makes.

Secondary information